Experiment Overview
| Repository ID: | FR-FCM-Z2KY | Experiment name: | Equine PBMC phenotyping during equine pegivirus infection | MIFlowCyt score: | 98.25% |
| Primary researcher: | Joy Tomlinson | PI/manager: | Troels Scheel | Uploaded by: | Joy Tomlinson |
| Experiment dates: | 2017-07-17 - 2020-02-15 | Dataset uploaded: | Apr 2020 | Last updated: | Apr 2024 |
| Keywords: | [PBMCs] [equine] [pegivirus] | Manuscripts: | |||
| Organizations: |
Cornell University College of Veterinary Medicine, Baker Institute for Animal Health, Ithaca, NY (United States)
|
||||
| Purpose: | One horse each was transfected by intrasplenic injection with clonal viral genomic RNA of Equine pegivirus-1 (EPgV1, aka pegivirus E) or Equine Pegivirus-2 (EPgV2, aka Pegivirus D, Theiler's disease associated virus). Each horse had peripheral blood mononuclear cells (PBMC) collected and phenotyped by flow cytometry every 2 weeks for 26 weeks to monitor immune response to infection. | ||||
| Conclusion: | No clear response in major PBMC subpopulations was observed in either horse. Horses did not clear the pegivirus infections within the 26 weeks of observation. It is possible that a response might have been observed around the time of viral clearance, and/or with finer detail of subpopulations or assessments for pegiviral-specific T cells (e.g. via ELISPOT). | ||||
| Comments: | None | ||||
| Funding: | This work was supported by grants from the Agriculture and Food Research Initiative Competitive Grant no. 2016-67015-24765 from the USDA National Institute of Food and Agriculture, the Zweig Equine Research Fund, and the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award number K08AI141767. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders, including the National Institutes of Health. | ||||
| Quality control: | Compensation beads were used for automated compensation. Flow cytometry panels were adapted from a previously validated panel: Tomlinson et al 2018 DOI: 10.1016/j.vetimm.2018.03.010. | ||||
Experiment variables
| Timepoints | |
|---|---|
| · pre-inoculation | EPgV1 panel M wk-4.fcs · EPgV1 panel M wk0.fcs · EPgV1 panel T wk-4.fcs · EPgV1 panel T wk0.fcs · EPgV2 panel M wk-5.fcs · EPgV2 panel M wk0.fcs · EPgV2 panel T wk-5.fcs · EPgV2 panel T wk0.fcs |
| · incubation period | EPgV1 panel M wk1.fcs · EPgV1 panel M wk2.fcs · EPgV1 panel T wk1.fcs · EPgV1 panel T wk2.fcs · EPgV2 panel M wk1.fcs · EPgV2 panel M wk2.fcs · EPgV2 panel T wk1.fcs · EPgV2 panel T wk2.fcs |
| · viremic period | EPgV1 panel M wk18.fcs · EPgV1 panel M wk28.fcs · EPgV1 panel M wk4.fcs · EPgV1 panel T wk18.fcs · EPgV1 panel T wk28.fcs · EPgV1 panel T wk4.fcs · EPgV2 panel M wk11.fcs · EPgV2 panel M wk15.fcs · EPgV2 panel M wk27.fcs · EPgV2 panel M wk5.fcs · EPgV2 panel T wk11.fcs · EPgV2 panel T wk15.fcs · EPgV2 panel T wk27.fcs · EPgV2 panel T wk5.fcs |
| Individuals | |
|---|---|
| · EPgV1 horse | EPgV1 panel M wk-4.fcs · EPgV1 panel M wk0.fcs · EPgV1 panel M wk1.fcs · EPgV1 panel M wk18.fcs · EPgV1 panel M wk2.fcs · EPgV1 panel M wk28.fcs · EPgV1 panel M wk4.fcs · EPgV1 panel T wk-4.fcs · EPgV1 panel T wk0.fcs · EPgV1 panel T wk1.fcs · EPgV1 panel T wk18.fcs · EPgV1 panel T wk2.fcs · EPgV1 panel T wk28.fcs · EPgV1 panel T wk4.fcs |
| · EPgV2 horse | EPgV2 panel M wk-5.fcs · EPgV2 panel M wk0.fcs · EPgV2 panel M wk1.fcs · EPgV2 panel M wk11.fcs · EPgV2 panel M wk15.fcs · EPgV2 panel M wk2.fcs · EPgV2 panel M wk27.fcs · EPgV2 panel M wk5.fcs · EPgV2 panel T wk-5.fcs · EPgV2 panel T wk0.fcs · EPgV2 panel T wk1.fcs · EPgV2 panel T wk11.fcs · EPgV2 panel T wk15.fcs · EPgV2 panel T wk2.fcs · EPgV2 panel T wk27.fcs · EPgV2 panel T wk5.fcs |
